All these speak to a gentle, holistic approach—Arialief strives for real healing and not just sedation of nerve signals. As ...

Growth in Specialty and Orphan Drug Approvals: The FDA’s focus on specialty medications and orphan drugs continues to expand, ...

Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced data from a poster ...

A company presentation is scheduled for Thursday, April 10, 2025, at 1:30 p.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section ...

HYDERABAD, India, April 03, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO) ...

See why thousands are using Prime Biome – Click here to learn more.

LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics ...

The Company also announces the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the Period. The 2024 Annual Report on Form 20-F can be found under ...

About IgG4-RD IgG4-RD affects approximatively eight out of 100,000 adult patients in the US each year and is a rare, progressive, relapsing, chronic fibro-inflammatory condition which can manifest in ...

After a distinguished career of 28 years with Novo Nordisk, hereof seven years as executive vice president of Commercial Strategy & Corporate Affairs, Camilla Sylvest has decided to leave the company.

Dr. Stefan Jentzsch, Partner at the global investment firm Perella Weinberg Partners has been appointed to Avextra’s Supervisory Board, bringing decades of experience in corporate finance, M&A, and ...

Mesoblast filed a request for a Type B meeting during the last quarter, in line with previous guidance, and expects to have the meeting during this quarter. The meeting will be held under Mesoblast’s ...